Bio-Techne
Precio: 54.02Empresa y modelo de negocio
Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.
Perfil de inversión
The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.
Métricas fundamentales
- EPS (TTM) — ganancias por acción de los últimos 12 meses, $
- 0.71 OK
- Ingresos QoQ — crecimiento trimestral de ingresos
- 5.3% ↑
- Sorpresa EPS
- -3.6% en línea
- Volatilidad 20d
- 2.8% estable
- Rendimiento de dividendos
- 0.6% bajo última fecha ex-div.: 2026-05-18
Seguir en portafolio
Gráfico de precio
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-05 02:49 | Vender | Mantener | Mixed performance; cautious outlook due to volatility. |
| 2026-05-30 02:52 | Mantener | Vender | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:11 | — | Mantener | Weak fundamentals and negative momentum raise significant concerns. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-05-14 20:21 | RBC Capital | Actualizar | — → 62 | 44.74 |
| 2026-05-07 12:07 | Evercore ISI | Objetivo reducido | 54 → 50 | 49.265 |
| 2026-05-07 11:26 | Stifel Nicolaus | Objetivo reducido | 65 → 50 | 47.405 |
Nada todavía